3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Esophageal Squamous Cell Carcinoma
5
Esophageal Neoplasms
3
Advanced Solid Tumor
3
Stomach Neoplasms
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Advanced Lung Cancer
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous NSCLC
1
Solid Tumor
1
SCLC
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Locally Advanced Rectal Cancer
1
Liver Neoplasms
1
Liver Diseases
1
High-Risk Resectable NSCLC
1
Gastrointestinal Diseases
1
Esophageal Diseases
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Capecitabine
4
Radiation
3
spartalizumab
2
Oxaliplatin
2
veliparib
1
toripalimab
1
tislelizumab
1
sintilimab
1
peposertib
1
XELOX
1
Radiotherapy
1
Irinotecan
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Locally Advanced Rectal Cancer
×
sintilimab
×
Clear all
NCT06493240
2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2
Completed
30 enrolled